Independent
Tenure on this board
1.8 yrs
Also a director at
Jazz Pharmaceuticals PLC (JAZZ)Vera Therapeutics Inc (VERA)Zenas Biopharma Inc (ZBIO)Veradermics Inc (MANE)
Meeting calendar
BIOA · Annual meeting · Wednesday, June 10, 2026
Bioage Labs Inc
3 nominees · 2 ballot items.
Vote to elect three Class II directors (Patrick Enright, James I. Healy, and Rekha Hemrajani) for three-year terms and to ratify KPMG LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Market cap
$1.0B
1Y TSR
+409.1%
Board grade
C
Record date
Apr 16, 2026
Filing
DEF 14A
Meeting concluded · Jun 10, 2026
Follow how the vote landed and what changed on Bioage Labs Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot2
- 1
Election of Class II Directors
ManagementBoard: FORElect three Class II directors (Patrick Enright, James I. Healy, and Rekha Hemrajani) to serve three‑year terms expiring in 2029.
- 2
Ratification of Independent Registered Public Accounting Firm
ManagementBoard: FORRatify the appointment of KPMG LLP as BioAge’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Director elections
Nominees on the ballot3
Independent
Tenure on this board
1.8 yrs
Also a director at
Rapport Therapeutics Inc (RAPP)Arrivent Biopharma Inc (AVBP)Seaport Therapeutics Inc (SPTX)
Independent
Tenure on this board
1.8 yrs
Also a director at
Alx Oncology Holdings Inc (ALXO)Maxcyte Inc (MXCT)Lb Pharmaceuticals Inc (LBRX)
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | a16z Capital Management, L.L.C. | 7.3% | 3,233,170 | $57M |
| 2 | Cormorant Asset Management, LP | 6.5% | 2,890,605 | $51M |
| 3 | Sofinnova Investments, Inc. | 5.2% | 2,293,788 | $40M |
| 4 | JANUS HENDERSON GROUP PLC | 4.7% | 2,094,270 | $37M |
| 5 | Octagon Capital Advisors LP | 3.9% | 1,748,000 | $31M |
| 6 | RA CAPITAL MANAGEMENT, L.P. | 3.7% | 1,650,648 | $29M |
| 7 | BlackRock, Inc. | 3.2% | 1,409,052 | $25M |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | 3.0% | 1,354,906 | $24M |
| 9 | BALYASNY ASSET MANAGEMENT L.P. | 3.0% | 1,327,545 | $23M |
| 10 | BRAIDWELL LP | 2.7% | 1,200,587 | $21M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Bioage Labs Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Avanos Medical IncAVNS
Special meeting·Jul 22, 2026·$1.2B
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$712M
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$1.6B
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.6B
Indaptus Therapeutics IncINDP
Annual meeting·Aug 10, 2026·$287M
Seer IncSEER
Annual meeting·Jul 28, 2026·$119M
Reference
Frequently asked questions
- When is the Bioage Labs Inc 2026 annual meeting?
- Bioage Labs Inc (BIOA) holds its 2026 annual shareholder meeting on Wednesday, June 10, 2026.
- What is the record date for the Bioage Labs Inc 2026 meeting?
- The record date for the Bioage Labs Inc 2026 meeting is Thursday, April 16, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Bioage Labs Inc's 2026 meeting?
- The board is presenting 3 director nominees at the Bioage Labs Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Bioage Labs Inc 2026 meeting?
- Shareholders will vote on 2 proposals at the Bioage Labs Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.